Craft
  • Home
  •  / Alnylam Pharmaceuticals
Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

Revenue

$844.3 M

FY, 2021

Market Capitalization

$25.8 B

2022-09-19

Alnylam Pharmaceuticals Summary

Company summary

Overview
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The Company’s pipeline focuses in three strategic therapeutic areas (STArs): genetic medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; cardio-metabolic disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases.
Type
Public
Founded
2002
HQ
Cambridge, MA, US | view all locations
Website
http://www.alnylam.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Yvonne Greenstreet

    Yvonne Greenstreet, Chief Executive Officer

  • Pushkal Garg

    Pushkal Garg, Chief Medical Officer

  • Al Boyle

    Al Boyle, Chief Technical Operations and Quality Officer

  • Laurie Keating

    Laurie Keating, Executive Vice President, Chief Legal Officer and Secretary

LocationsView all

8 locations detected

  • Cambridge, MA HQ

    United States

    675 W Kendall St

  • Paris, IDF

    France

    100 Av. de Suffren

  • Milano, Lombardia

    Italy

    Via Pola, 11

  • Chiyoda City, Tokyo

    Japan

    11th Floor of Pacific Century Place Marunouchi 1-11-1 Marunouchi

  • Amsterdam, NH

    Netherlands

    Strawinskylaan 3051

  • Stockholm, Stockholms län

    Sweden

    Olof Palmes gata 29

and 2 others

Alnylam Pharmaceuticals Financials

Summary financials

Revenue (Q2, 2022)
$213.5M
Cash (Q2, 2022)
$575.6M
Enterprise value
$26.2B

Footer menu